A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-01 and is reviewed periodically as new material appears.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
=== Stannane === Organostannane reagents are common. Several are commercially available. Stannane reagents can be synthesized by the reaction of a Grignard or organolithium reagent with trialkyltin chlorides. For example, vinyltributyltin is prepared by the reaction of vinylmagnesium bromide with tributyltin chloride. Hydrostannylation of alkynes or alkenes provides many derivatives. Organotin reagents are air and moisture stable. Some reactions can even take place in water. They can be purified by chromatography. They are tolerant to most functional groups. Some organotin compounds are heavily toxic, especially trimethylstannyl derivatives. The use of vinylstannane, or alkenylstannane reagents is widespread. In regards to limitations, both very bulky stannane reagents and stannanes with substitution on the α-carbon tend to react sluggishly or require optimization. For example, in the case below, the α-substituted vinylstannane only reacts with a terminal iodide due to steric hindrance.
The LCPO method uses a linear approximation of the two-body problem for a quicker analytical calculation of ASA. The approximations used in LCPO result in an error in the range of 1-3 Ų. In 2011, a method was presented that calculates ASA fast and analytically using a power diagram. Accessible surface area is often used when calculating the transfer free energy required to move a biomolecule from an aqueous solvent to a non-polar solvent, such as a lipid environment. The LCPO method is also used when calculating implicit solvent effects in the molecular dynamics software package AMBER. It is recently suggested that (predicted) accessible surface area can be used to improve prediction of protein secondary structure.
The entries in BTO are updated bi-annually as part of the major update of BRENDA. It is available via the BRENDA website in the category “Ontology Explorer”. The enzyme source terms can be searched via the BTO query form. As a result, the user receives a list of EC numbers which are directly connected to the enzyme information of BRENDA. It is also possible to search via the BRENDA “Source Tissue” search form (“Classic View”). The result page displays all enzymes which are isolated or detected in the searched tissue term, directly linked to BTO. BTO and BRENDA are freely accessible for academic users. It can be freely downloaded via the “Ontology Explorer” of the BRENDA website or in the OBO format from “Obofoundry”. BTO (BRENDA Tissue Ontology) BRENDA Ontology Explorer BRENDA-website ExplorEnz – Enzyme Nomenclature Obofoundry Gene Ontology Consortium EBI-EMBL Bioportal des National Center for Biomedical Ontology, Stanford, USA
Hippocrates in his writings discussed the use of silver in wound care. At the beginning of the twentieth century surgeons routinely used silver sutures to reduce the risk of infection. In the early 20th century, physicians used silver-containing eyedrops to treat ophthalmic problems, for various infections, and sometimes internally for diseases such as tropical sprue, epilepsy, gonorrhea, and the common cold. During World War I, soldiers used silver leaf to treat infected wounds. In the 1840s, founder of gynecology J. Marion Sims employed silver wire, which he had a jeweler fashion, as a suture in gynecological surgery. This produced very favorable results when compared with its predecessors, silk and catgut. Prior to the introduction of modern antibiotics, colloidal silver was used as a germicide and disinfectant. With the development of modern antibiotics in the 1940s, the use of silver as an antimicrobial agent diminished, although it retains some use in medicinal compounds today. Silver sulfadiazine (SSD) is a compound containing silver and the antibiotic sodium sulfadiazine, which was developed in 1968.
MiRNA expression profiles are altered in psychiatric conditions, including depression, anxiety, and PTSD. It has been demonstrated that miR-324-5p expression is altered in the brains of suicide victims with depression and in the amygdala, the fear center of the brain, in PTSD. MiRNAs are an underexplored potential biomarker and target for treatment for psychiatric disease. miRNA-324-5p is a relatively new and understudied microRNA. It is an important regulator in several diseases, and its effects span across the body from neuronal dysregulation in seizure to hepatocellular carcinoma and cardiac disease. Because microRNAs have numerous targets, they are capable of regulating multiple pathways and circuits, an ability that may be useful in the treatment of complex disorders like epilepsy in which many subsystems are dysregulated. However, the wide-ranging functions of miRNAs may be limiting as well. microRNA expression modulation could lead to unanticipated physiological effects and not provide adequate specificity.
Sources: en.wikipedia.org
Tissue engineering aims to generate functional constructs which could replace or improve damaged or infected tissues or whole organs. Many of these constructs lead to infected tissue around the implant area. Coating these materials in amylopectin allows reduction in this infectious reaction. Since amylopectin is mainly used as a coating around these constructs in as it prevents following immune reactions. Since amylopectin is derived directly from a natural polysaccharide, it integrates well with tissues and cells. However, mechanical properties of amylopectin are not optimal due to its high level of crosslinking. This can be avoided by the formation of amylopectin fibers or by forming a nanocomposite with another more rigid polymer.
== Production == Alliance Medical and Siemens Healthcare are the only producers in the United Kingdom. A dose of FDG in England costs about £130. In Northern Ireland, where there is a single supplier, doses cost up to £450. IBA Molecular North America and Zevacor Molecular, both of which are owned by Illinois Health and Science (IBAM having been purchased as of 1 August 2015), Siemens' PETNET Solutions (a subsidiary of Siemens Healthcare), and Cardinal Health are producers in the U.S.
== Historical consequences == The history of tolbutamide has had a lasting effect on medicine and the pharmaceutical industry. Patients today are still diagnosed with prediabetes, many of them managing to delay the onset of diabetes through dietary and lifestyle changes, but many also have the option to take metformin, which demonstrated a 31% reduction in three-year incidence of development of diabetes relative to placebo. While impressive, the lifestyle-modification arm of that same trial demonstrated a 58% reduction.
At 80 years old, Donald Trump, the 45th and 47th president of the United States, became the oldest person in American history to become president upon his second inauguration in 2025. In July 2024, five weeks after his 78th birthday, he became the oldest presidential nominee of a major party. Should he serve as president until at least August 15, 2028, he would be the oldest sitting president in American history. On January 20, 2029, the end of his second term, he would be 82 years, seven months, and six days old. Since the early days of Trump's 2016 presidential campaign, his physical and mental health have been debated. Trump was 70 years old when he first took office, surpassing Ronald Reagan as the oldest person to assume the presidency. Trump's age, weight, lifestyle, and history of heart disease raised questions about his physical health. Some psychiatrists and reporters have speculated that Trump may have mental health impairments, such as dementia (which his father had), attention deficit hyperactivity disorder or narcissistic personality disorder. Such claims have prompted discussion about the ethics and applicability of the Goldwater rule, which prohibits mental health professionals from publicly diagnosing or discussing the diagnosis of public figures without their consent and direct examination. Public opinion polling from July 2024 indicated an increase in the percentage of Americans concerned about his fitness for a second term.
== Further reading == Ye, Yanqi; Yu, Jicheng; Gu, Zhen (2015). "Versatile Protein Nanogels Prepared by In Situ Polymerization". Macromolecular Chemistry and Physics. 217 (3): 333–343. doi:10.1002/macp.201500296. Yan, Ming; Ge, Jun; Liu, Zheng; Ouyang, Pingkai (2006). "Encapsulation of Single Enzyme in Nanogel with Enhanced Biocatalytic Activity and Stability". Journal of the American Chemical Society. 128 (34): 11008–9. Bibcode:2006JAChS.12811008Y. doi:10.1021/ja064126t. PMID 16925402. Reese, Chad E.; Mikhonin, Alexander V.; Kamenjicki, Marta; Tikhonov, Alexander; Asher, Sanford A. (2004). "Nanogel Nanosecond Photonic Crystal Optical Switching". Journal of the American Chemical Society. 126 (5): 1493–6. Bibcode:2004JAChS.126.1493R. doi:10.1021/ja037118a. PMID 14759207. Lee, Eun Seong; Kim, Dongin; Youn, Yu Seok; Oh, Kyung Taek; Bae, You Han (2008). "A Virus-Mimetic Nanogel Vehicle". Angewandte Chemie International Edition. 47 (13): 2418–21. Bibcode:2008ACIE...47.2418L. doi:10.1002/anie.200704121. PMC 3118583. PMID 18236507. Hasegawa, Urara; Nomura, Shin-Ichiro M.; Kaul, Sunil C.; Hirano, Takashi; Akiyoshi, Kazunari (2005). "Nanogel-quantum dot hybrid nanoparticles for live cell imaging". Biochemical and Biophysical Research Communications. 331 (4): 917–21. Bibcode:2005BBRC..331..917H. doi:10.1016/j.bbrc.2005.03.228. PMID 15882965. Du, Jin-Zhi; Sun, Tian-Meng; Song, Wen-Jing; Wu, Juan; Wang, Jun (2010). "A Tumor-Acidity-Activated Charge-Conversional Nanogel as an Intelligent Vehicle for Promoted Tumoral-Cell Uptake and Drug Delivery".
Sources: en.wikipedia.org
==== Silk crepeline ==== Silk crepeline is less sheer than nylon netting and is also susceptible to reactions to light, but may be used as an overlay technique as well as for patching specific areas and can be easily dyed. Because it can fray, the edges need to be hemmed, which can create less sheer areas.
== Activating and inhibiting agents == The SC-FAs that activate FFAR3 include proprionic, butyric, acetic, valeric caproic, and formic acids. (Confusingly, butyric acid also activates hydroxycarboxylic acid receptor 2 and β-hydroxybutyric acid has been reported to stimulate or inhibit FFAR3.) FFAR2 is activated by many of these same SC-FAs but differs from FFAR3 in its relative binding affinities for them. In humans, the binding affinity ranking of FFAR3 is: propionic = butyric = valeric > acetic > formic acids (acetic and formic acids have very low binding affinities for, and therefore must be at extremely high levels to activate, FFAR3); FFAR2's relative binding affinity ranking for these SC-FAs is: acetic = propionic > butyric > valeric = formic acids. AR420626 (a derivative of an older compound 1-MCPC) has been reported to be a selective activator of FFAR3 but has also been reported to inhibit the activation of FFAR3. Its actions require further characterizations. AR399519 and CF3-MQC have been reported to inhibit the activation of mouse FFAR3; the actions of these agents also require further characterizations.
Issues can be due to non-volatile substances remaining in the drops, which can change the efficiency of droplet formation or droplet evaporation, which in turn affects the amount of charged ions in the gas phase that ultimately reach the mass spectrometer. These problems can be fixed in multiple ways, including increasing the amount of concentration of analyte compared to matrix in the sample solution or by running the sample through a more extensive chromatographic technique before analysis. An example of a chromatographic technique that can aid in signal in ESI involves using 2-D liquid chromatography, or running the sample through two separate chromatography columns, giving better separation of the analyte from the matrix.
In August 2025, the United States began a military buildup in the southern Caribbean, deploying warships and military personnel. The Central Intelligence Agency (CIA) sent a team into Venezuela that began tracking Maduro's movements, using a source close to the Venezuelan president, and plans were made for the capture of Maduro months in advance. The Delta Force and other participants in the operation erected a mockup of the safe house in which Maduro was believed to be hiding, described by Trump as a "very highly guarded ... fortress". In September, the United States Southern Command began conducting military strikes on vessels in the Caribbean Sea, alleging some were trafficking drugs on behalf of Venezuela. In November 2025, Venezuelan opposition leader María Corina Machado promised to open Venezuela's oil and gas reserves during a business meeting in Miami attended by Trump, and the Trump administration engaged in secret talks with Maduro's government about its oil reserves. In December 2025, this escalated to include seizures of sanctioned oil tankers carrying Venezuelan crude. These seizures formed part of the broader blockade on sanctioned oil preceding the January 2026 operation. The US also launched covert operations in Venezuela under the directive of the CIA in late December. On 2 January 2026, Trump announced that the US military would conduct strikes inside Venezuela. In the weeks preceding the operation, Trinidad and Tobago signed an agreement with the US to allow US military access to its airports.
=== Tentoxin === Tentoxin is most commonly known as a naturally occurring phytotoxic cyclic tetra-peptide that is excreted by fungi of the Alternaria alternata family. There were four total syntheses of tentoxin that were published to this day that gave very poor total yields. These poor yields were mainly due to the introduction of the dehydro amino acid, more specifically the cyclization step. There was a method developed in order to stereospecifically introduce Z-dehydrophenylalanine by a modified Erlenmeyer adolization reaction. An aldol reaction is a transformation that is due to the dimerization of an aldehyde (or ketone) to a beta-hydroxy aldehyde (or ketone) by alpha C-H addition of one reactant molecule to the carbonyl group of a second reactant molecule. This reaction requires at least one of the reactants to have hydrogens. The precursor of tentoxin, the linear tetrapeptide (Boc-R1Ala-Leu-R2ΔZPhe-Gly-OMe), was obtained from Boc-Leu-Gly-OH with a 72% yield. This linear tetrapeptide with carbon-14 was utilized to study the four cyclization reagents, DPPA, DCC-PfpOH, HBTU, and HATU. By doing so, this gave the tentoxin an 81% cyclization yield.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.